Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03048617 · ClinicalTrials.gov registry record
An Observational Study of Patients With Primary Mitochondrial Disease (SPIMM-300)
A clinical trial, sponsored by Stealth BioTherapeutics.
- Completed
- Registry status
- 215
- Enrollment target
NCT03048617: Completed study, sponsored by Stealth BioTherapeutics.
NCT03048617 is a clinical trial that has completed, run by Stealth BioTherapeutics. The registered enrollment target is 215 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03048617 has completed, sponsored by Stealth BioTherapeutics.
- COMPLETED
- Registry status
- 215 participants
- Enrollment target
Study Summary
This is an observational study of patients with Primary Mitochondrial Disease with either signs or symptoms suggestive of myopathy. The Investigator will identify potential patients through existing medical records and one on-site visit.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2017-02-13 |
| Est. Completion | 2019-03-07 |
What the finished NCT03048617 record still lists
NCT03048617 is an observational study that tracks outcomes without assigning an intervention. The registered 215 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03048617 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03048617 about?
NCT03048617 is a clinical study titled "An Observational Study of Patients With Primary Mitochondrial Disease (SPIMM-300)". This is an observational study of patients with Primary Mitochondrial Disease with either signs or symptoms suggestive of myopathy. The Investigator will identify potential patients through existing medical records and one on-site visit.
What is the current status of trial NCT03048617?
This trial is currently completed. The enrollment target is 215 participants. The study started on 2017-02-13. Estimated completion is 2019-03-07.
Who is sponsoring clinical trial NCT03048617?
This trial is sponsored by Stealth BioTherapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05134012 · 215 participants · Phase 3
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
- NCT05169970 · 215 participants · Phase 2
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
- NCT05197270 · 215 participants · Phase 1
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
- NCT05230199 · 215 participants · NA
Sensory Optimization of the Hospital Environment
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI